204 related articles for article (PubMed ID: 27160477)
1. Ixazomib for multiple myeloma.
Burki TK
Lancet Oncol; 2016 Jun; 17(6):e228. PubMed ID: 27160477
[No Abstract] [Full Text] [Related]
2. Ixazomib in the management of relapsed multiple myeloma.
Touzeau C; Moreau P
Future Oncol; 2018 Aug; 14(20):2013-2020. PubMed ID: 29469592
[TBL] [Abstract][Full Text] [Related]
3. Spotlight on ixazomib: potential in the treatment of multiple myeloma.
Muz B; Ghazarian RN; Ou M; Luderer MJ; Kusdono HD; Azab AK
Drug Des Devel Ther; 2016; 10():217-26. PubMed ID: 26811670
[TBL] [Abstract][Full Text] [Related]
4. Ixazomib for the treatment of multiple myeloma.
Gentile M; Offidani M; Vigna E; Corvatta L; Recchia AG; Morabito L; Morabito F; Gentili S
Expert Opin Investig Drugs; 2015; 24(9):1287-98. PubMed ID: 26138345
[TBL] [Abstract][Full Text] [Related]
5. Ixazomib: First Global Approval.
Shirley M
Drugs; 2016 Mar; 76(3):405-11. PubMed ID: 26846321
[TBL] [Abstract][Full Text] [Related]
6. Ixazomib Treatment of IgA Multiple Myeloma With Hyperviscosity Syndrome.
Boiten HJ; Buijze M; Zweegman S; Levin MD
Clin Lymphoma Myeloma Leuk; 2020 Nov; 20(11):e832-e835. PubMed ID: 32690387
[No Abstract] [Full Text] [Related]
7. Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma.
Al-Salama ZT; Garnock-Jones KP; Scott LJ
Target Oncol; 2017 Aug; 12(4):535-542. PubMed ID: 28660423
[TBL] [Abstract][Full Text] [Related]
8. Oral therapy for multiple myeloma: ixazomib arriving soon.
Moreau P
Blood; 2014 Aug; 124(7):986-7. PubMed ID: 25124778
[TBL] [Abstract][Full Text] [Related]
9. The investigational proteasome inhibitor ixazomib for the treatment of multiple myeloma.
Richardson PG; Moreau P; Laubach JP; Gupta N; Hui AM; Anderson KC; San Miguel JF; Kumar S
Future Oncol; 2015; 11(8):1153-68. PubMed ID: 25832873
[TBL] [Abstract][Full Text] [Related]
10. Ixazomib: a novel drug for multiple myeloma.
Zanwar S; Abeykoon JP; Kapoor P
Expert Rev Hematol; 2018 Oct; 11(10):761-771. PubMed ID: 30173621
[TBL] [Abstract][Full Text] [Related]
11. Ixazomib inhibits myeloma cell proliferation by targeting UBE2K.
Wang Q; Dong Z; Su J; Huang J; Xiao P; Tian L; Chen Y; Ma L; Chen X
Biochem Biophys Res Commun; 2021 Apr; 549():1-7. PubMed ID: 33647537
[TBL] [Abstract][Full Text] [Related]
12. Ixazomib for the treatment of multiple myeloma.
Richardson PG; Zweegman S; O'Donnell EK; Laubach JP; Raje N; Voorhees P; Ferrari RH; Skacel T; Kumar SK; Lonial S
Expert Opin Pharmacother; 2018 Dec; 19(17):1949-1968. PubMed ID: 30422008
[TBL] [Abstract][Full Text] [Related]
13. Drugs: More shots on target.
Appel A
Nature; 2011 Dec; 480(7377):S40-2. PubMed ID: 22169800
[No Abstract] [Full Text] [Related]
14. Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial.
Mina R; Falcone AP; Bringhen S; Liberati AM; Pescosta N; Petrucci MT; Ciccone G; Capra A; Patriarca F; Rota-Scalabrini D; Bonello F; Musolino C; Cea M; Zambello R; Tacchetti P; Belotti A; Cellini C; Paris L; Grasso M; Aquino S; De Paoli L; De Sabbata G; Ballanti S; Offidani M; Boccadoro M; Monaco F; Corradini P; Larocca A
Blood Cancer J; 2021 Dec; 11(12):197. PubMed ID: 34876566
[No Abstract] [Full Text] [Related]
15. Acute Pancreatitis Associated with Ixazomib in a Multiple Myeloma Patient.
Steiner RE; Orlowski RZ; Lee HC
Acta Haematol; 2018; 139(1):67-70. PubMed ID: 29402766
[TBL] [Abstract][Full Text] [Related]
16. Pooled analysis of the reports of carfilzomib/ixazomib combinations for relapsed/refractory multiple myeloma.
Xu W; Sun X; Wang B; Guo H
Ann Hematol; 2018 Feb; 97(2):299-307. PubMed ID: 29159498
[TBL] [Abstract][Full Text] [Related]
17. Three new drugs for multiple myeloma.
Med Lett Drugs Ther; 2016 May; 58(1495):e70-1. PubMed ID: 27192621
[No Abstract] [Full Text] [Related]
18. Accidental Ixazomib Overdose in a Patient With Multiple Myeloma.
Sampat PJ; Bisen M; Srivastava N; Rao S; Gentile T
J Investig Med High Impact Case Rep; 2021; 9():23247096211013230. PubMed ID: 33980053
[TBL] [Abstract][Full Text] [Related]
19. Model-Informed Drug Development for Ixazomib, an Oral Proteasome Inhibitor.
Gupta N; Hanley MJ; Diderichsen PM; Yang H; Ke A; Teng Z; Labotka R; Berg D; Patel C; Liu G; van de Velde H; Venkatakrishnan K
Clin Pharmacol Ther; 2019 Feb; 105(2):376-387. PubMed ID: 29446068
[TBL] [Abstract][Full Text] [Related]
20. Ixazomib maintenance therapy in newly diagnosed multiple myeloma: An integrated analysis of four phase I/II studies.
Dimopoulos MA; Laubach JP; Echeveste Gutierrez MA; Grzasko N; Hofmeister CC; San-Miguel JF; Kumar S; Labotka R; Lu V; Berg D; Byrne C; Teng Z; Liu G; van de Velde H; Richardson PG
Eur J Haematol; 2019 Jun; 102(6):494-503. PubMed ID: 30943323
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]